Edition:
India

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

117.57USD
2:29am IST
Change (% chg)

$6.75 (+6.09%)
Prev Close
$110.82
Open
$131.50
Day's High
$131.87
Day's Low
$115.30
Volume
1,508,300
Avg. Vol
165,555
52-wk High
$133.71
52-wk Low
$58.05

Latest Key Developments (Source: Significant Developments)

Intercept Announces NASH And PBC Program Updates
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Intercept Pharmaceuticals Inc ::INTERCEPT ANNOUNCES NASH AND PBC PROGRAM UPDATES.INTERCEPT PHARMACEUTICALS INC - PHASE 3 REVERSE TRIAL OF OCA IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS PROJECTED TO COMPLETE ENROLLMENT IN 2019.INTERCEPT PHARMACEUTICALS INC - INTERCEPT ACQUIRES LICENSE TO U.S. DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO PAN-PPAR AGONIST BEZAFIBRATE.INTERCEPT- DATA FROM INTERIM ANALYSIS OF PHASE 3 REGENERATE TRIAL OF OBETICHOLIC ACID IN NASH PATIENTS WITH ADVANCED FIBROSIS ANTICIPATED IN Q1 2019.INTERCEPT PHARMACEUTICALS INC - HAS ACQUIRED FROM ARALEZ PHARMACEUTICALS INC. ITS LICENSE TO DEVELOP AND COMMERCIALIZE BEZAFIBRATE IN U.S..  Full Article

Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31
Thursday, 5 Apr 2018 

April 4 (Reuters) - Intercept Pharmaceuticals Inc ::EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​.  Full Article

Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Intercept Pharmaceuticals Inc ::INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY.INTERCEPT PHARMA SAYS LAWSUIT WAS FILED BY A STOCKHOLDER OF CO ON AUG 4, 2017 - SEC FILING.  Full Article

Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Intercept Pharmaceuticals Inc ::INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING.  Full Article

Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update.Intercept - ‍non-GAAP adjusted operating expenses for fiscal year ending Dec 31, 2017 will fall in middle of range of $380 million to $420 million​.Intercept Pharmaceuticals - ‍interim analysis in flagship Phase 3 regenerate trial on track to report in H1 2019.Intercept Pharmaceuticals Inc- to streamline operating expenses, decided to deprioritize interest-767 development program for foreseeable future​.Intercept Pharmaceuticals Inc - qtrly ‍rev $41.3 million versus $5.2 million​.Q3 earnings per share view $-3.38, revenue view $37.0 million -- Thomson Reuters I/B/E/S.Intercept Pharmaceuticals inc qtrly net loss per common and potential common share basic and diluted $2.89‍​.  Full Article

Intercept Pharma posts positive results from Phase 2 AESOP trial
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Intercept Pharmaceuticals Inc :Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017.Intercept Pharmaceuticals Inc - ‍OCA met primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks​.  Full Article

Intercept extends strategic partnership with Target PharmaSolutions for Target-Nash
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Intercept Pharmaceuticals Inc :Intercept (ICPT) extends strategic partnership with Target PharmaSolutions for Target-Nash.Target PharmaSolutions - Intercept has extended its strategic partnership for Target-Nash to a multi-year agreement​.  Full Article

Intercept's fatty liver drug meets late-stage main goal, shares soar

Intercept Pharmaceuticals Inc said on Tuesday its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ, taking the drug a step closer to approval and sending the company's shares surging 25 percent.